PCM
ZYNE

Prelude Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Prelude Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,769
Closed -$6K – 2495
2020
Q2 		$6K Buy
+1,769
New +$8.37K ﹤0.01% 1699
2016
Q3 		– Sell
-2,000
Closed -$14K – 1880
2016
Q2 		$14K Buy
+2,000
New +$16.7K ﹤0.01% 1358

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prelude Capital Management's ZYNE Position: Q3 2020 in Review

Prelude Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 1,769 shares — an estimated $6K sold.

Prelude Capital Management first reported a position in ZYNE in Q2 2016 and held it in 2 quarters. The position peaked at $14K in Q2 2016. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

  • Prelude Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 1,769 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $6K.
  • Prelude Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 2 quarters.
  • Prelude Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $14K in Q2 2016.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.